Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
Abdulrahman Nasiri/LinkedIn
Mar 15, 2026, 13:57

Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies

Abdulrahman Nasiri, Assistant Professor at Imam Muhammad ibn Saud Islamic University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

“Proud to share our newly published review in Technology in Cancer Research and Treatment: ‘Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Induction: The End of Story or Not Yet?

For years, the Day 14 bone marrow biopsy (D14 BMB) has guided AML treatment decisions, where less than five percent blasts strongly predicted complete remission following standard seven plus three induction.

However, as the treatment landscape shifts toward targeted therapies, we must re-evaluate this gold standard.

In our review, we explore:

  • Evolving Kinetics: Novel agents like venetoclax induce slower blast clearance, meaning traditional D14 assessments may now be premature.
  • Cellularity as a marker: Hypocellularity (less than twenty percent) remains a crucial, independent predictor of superior overall survival.
  • The re-induction dilemma: Second-course therapy for persistent blasts increases remission rates but does not consistently translate to an overall survival benefit and carries significant morbidity risks.
  • The shift to mrd: High-sensitivity Measurable Residual Disease (MRD) monitoring is increasingly becoming the standard for precise, long-term prognostic evaluation and risk stratification.

Our key takeaway: D14 BMB is not obsolete, but it must now be integrated into a risk-adapted framework that accounts for specific treatment modalities and MRD status.”

Title: Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Induction: The End of Story or Not Yet?

Authors: Mostafa F. Mohammed Saleh, Abdulrahman Nasiri, Ahmed Abdrabou, Ali Alahmari, Syed O. Ahmed, Ayman Saad, Mahmoud Aljurf

Read Full Article on Sages Journals

Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies

Stay updated on all scientific advances with Hemostasis Today.

Abdulrahman Nasiri Ahmed Abdrabou Ali Alahmari Ayman Saad bleeding disorders haemophilia Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Mahmoud Aljurf Mostafa F. Mohammed Saleh Syed O. Ahmed
NewsFeed